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The b 1 -adrenergic receptor (b 1 -AR) belongs to the largest super family of G-protein-coupled receptors (GPCRs). The b 1 -AR responds to norepinephrine and epinephrine by activating adenylyl cyclase pathway and promotes production of cAMP. 1) Activation of cardiac b-adrenergic receptors plays an important role in regulating the physiological responses of the heart to an increase demand.
2) The pathophysiology of human b 1 -ARs is associated with several cardiovascular diseases such as dilated cardiomyopathy, congestive heart failure, ventricular arrhythmia and sudden death. [3] [4] [5] Recently, several GPCRs have exhibited constitutive activity and inactivity in vivo. Naturally occurring amino acid mutations in the luteinizing hormone receptor, 6) parathyroid hormone receptor, 7) melanocyte-stimulating hormone receptor, 8) thyrotropin receptor 9) and rhodopsin receptor 10) result in constitutive activation of second messenger production and are thought to play a role in disease pathophysiology. Constitutively active mutant receptors have been a valuable tool to demonstrate that certain ligands stabilize inactive conformations. Those ligands are known as inverse agonist, given that they have the opposite effect of agonists. Therefore, b-antagonists are used clinically to reduce heart rate and force of contraction in hypertension, angina and acute myocardial infarction by direct blocking endogenous catecholamine activity, [11] [12] [13] implying that inverse agonists may have preferred therapeutic applications in the pathophysiology of several cardiovascular diseases.
In all seven transmembrane helix (TMH) of GPCRs it appears that the general mechanism of activation involves disruption of intramolecular constraints, leading to TMH movement and formation of new interactions, which stabilize the active state of the receptor. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The aspartic acid at position 104 in TMH II of the human b 1 -AR is conserved in all b-adrenergic [28] [29] [30] [31] , a-adrenergic receptor 32) and also muscarinic cholinergic receptors, [33] [34] [35] which may take part in an ionic interaction with amino group containing catecholamines, whose disruption of interaction makes the receptor active conformation state. It was reported by Chung et al. 36) that aspartic acid residue at position 79 in putative TMH II of b 2 -AR was involved in agonist binding and receptor activation. Substitution of aspartic acid to alanine and asparagine at position 79 did not affect the antagonist binding but significantly decreased the binding affinity of agonists. 37) Moreover, this mutant receptor also affected the functional activity compared to wild type receptor by uncoupling with GPCRs.
With the help of molecular modeling, we previously identified the important binding sites of b 1 -AR. We showed that Asp104 in TMH II of b 1 -AR makes strong electrostatic interaction with functional groups of SWR-0342SA. 38 ) Through mutagenesis studies, we suggested that Asp104 is very important site for the ligand binding and functional activity. We also showed that mutation of negatively charged aspartic acid to neutral charged alanine exhibited constitutive activity of b 1 -AR. 39) However, the mutation of negatively charged aspartic acid to positively charged lysine is still remained to be ex- amined. At the present study, we have mutated aspartic acid to lysine (Asp104Lys) residue of human b 1 -AR and investigated the ligand binding, functional characteristic and constitutive activation of Asp104Lys mutant of human b 1 -AR. This resultant mutant (Asp104Lys) did not affect the antagonist binding, but significantly decreased the binding affinity of isoproterenol and (Ϫ)-epinephrine. Moreover, mutant receptor exhibited lower extent of agonist induced cAMP production, which made the receptor functionally inactive state. Additionally, we assessed the basal cAMP accumulation of Asp104Lys mutant that was decreased in comparison with the basal level of wild type receptor.
The objectives of this study are the construction of mutant Asp104Lys of b 1 -AR by site-directed mutagenesis and the analysis of their interactions with several agonists and antagonists by radioligand binding assay. We have also demonstrated that aspartic acid at position 104 in TMH II of human b 1 -AR is highly conserved for agonist binding and it plays an important role for receptor functional response mediated by coupling with GPCRs.
MATERIALS AND METHODS

Mutagenesis of cDNA and Transfection
The cDNA encoding human b 1 -AR in pCMV5 was a kind gift from Dr. Lefkowitz at Duke University Medical Center, Durham, NC, U.S.A. We prepared the Asp104Lys mutant by QuikChange ® site-directed mutagenesis kit (Stratagene, CA, U.S.A.), according to manufacturer's protocol. This mutant receptor was confirmed by DNA sequencing analysis (Beckman Coulter CEQ2000XL, CA, U.S.A.). HEK293 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. Stably expressing cells lines were constructed in HEK293 cells by transfecting with Lipofectamine TM 2000 reagent (Invitrogen Life Technology, CA, U.S.A.) and selected with 0.5 mg/ml G418-containing growth medium as described by the manufacturer's protocol.
Membrane Preparation from HEK293 Cells The transfected HEK293 cells were rinsed twice with 3 ml of icecold homogenize buffer containing 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, and 2 mM EDTA and mechanically detached by cell scraper. The cells were homogenized using Ultra-Turrax homogenizer (Ika Labortechnik, Germany) and after removal of nuclei by centrifugation at 3000ϫg for 5 min, the membrane fractions centrifuged at 45000ϫg for 30 min at 4°C. The resultant pellets were resuspended by Teflon homogenizer in assay buffer containing 75 mM Tris-HCl (pH 7.4), 12.5 mM MgCl 2 , 2 mM EDTA and kept frozen at Ϫ80°C until used. Protein concentrations of the membrane fractions were measured by the method of Lowry et al. using bovine serum albumin as the standard. 40) Ligand Binding Crude membranes were prepared from cells expressing the b 1 -AR and its mutant. Radioligand binding studies were carried out in assay buffer containing 75 mM Tris-HCl (pH 7.4), 12.5 mM MgCl 2 and 2 mM EDTA at 37°C for 60 min using 5-10 mg of membrane protein. The total reaction volume was 250 ml. For saturation isotherms, membranes were incubated with varying concentrations (10-2000 pM) of [ 3 H]-CGP12177 (GE Healthcare Biosciences, Piscataway, U.S.A.) in the absence (total binding) or presence (nonspecific binding) of 1 mM 1-propranolol. Competition binding studies were carried out using 100 pM [ 3 H]-CGP12177 for wild type b 1 -AR and 300 pM for Asp104Lys mutant of b 1 -AR. The reactions were stopped by rapid filtration using Brandel cell harvester over Whatman GF/C glass fiber filters that had been treated with 0.1% polyethylenimine followed by washing with 4 ml cold wash buffer containing 25 mM Tris-HCl (pH 7.5) and 1 mM MgCl 2 . The radioactivity remaining on the filter was counted by liquid scintillation counting.
cAMP Accumulation Assay cAMP accumulation assay was described previously. 39) In brief, adherent cells in 12-well plates (5ϫ10 5 cells/well) were incubated for 30 min at 37°C in 500 ml/well of Hank's balance salt solution (HBSS) buffered with 25 mM HEPES, 1 mM ascorbic acid and 1 mM isobutyl-methylxanthine (Sigma, St. Louis, U.S.A.), in the presence of agonist or other drugs. The reaction was stopped by washing twice with 1 ml ice cold (Ϫ) phosphate buffered saline and immediate addition of 250 ml 1 N NaOH. After 20 min at 37°C the samples were neutralized with 1 N acetic acid and the dissolved cells were centrifuged at 3000ϫg for 10 min at 4°C. The amount of cAMP produced was determined on 50 ml of supernatant using Amersham [
3 H]cAMP assay kit (GE Healthcare Biosciences, Piscataway, U.S.A.) according to manufacturer's protocol.
Western Blot Analysis Stably transfected HEK 293 cells expressing b 1 -AR wild type and mutant receptors were constructed according to the methods described above. Equal amounts of protein samples were resolved by SDS-polyacrylamide gel electrophoresis (10% gradient gels) and transferred onto Hybond ECL nitrocellulose membranes (Amersham Biosciences, U.S.A.) using a semi dry system in immunotransfer buffer. The membranes were blocked in blocking buffer (PBS with 5% nonfat dried milk) overnight at 4°C and incubated for 1 h at room temperature with anti-rabbit b 1 -AR polyclonal antibody (Santa Cruz Inc., California, U.S.A.) at 1 : 1000 dilutions in blocking buffer. The membranes were washed three times with tris-buffer saline (TBS) containing 0.1% Tween-20 and incubated with alkaline phosphatase-conjugated anti-rabbit IgG (Promega, U.S.A.) for 1 h at room temperature at 1 : 5000 dilutions in blocking buffer. The membranes were washed and then the proteins on the membranes were visualized by adding Western blue (Promega, U.S.A.) as a substrate.
Data Analysis Nonlinear regression analysis of saturation and competition binding assay were performed using GraphPad Prism software (San Diego, CA, U.S.A. Competition Binding In competition binding experiment, the binding affinity (pK i ) of isoproterenol and epinephrine to both wild type and mutant (Asp104Lys) receptors were markedly decreased. The binding affinity of isoproterenol and (Ϫ)-epinephrine for mutant Asp104Lys was decreased 112 fold and 10 fold respectively in compared to wild type (pϽ0.05). However, antagonists binding did not change for both mutant receptors, (Table 1, Fig. 1 ). Moreover, pK i values of several other agonists and antagonists of b 1 -ARs were shown for a comparative study with wild type and both mutant (Asp104Ala and Asp104Lys) receptors in Table 1 .
Isoproterenol Stimulated cAMP Accumulation As cAMP accumulation is changed with the b 1 -ARs activation or inactivation, we have examined the constitutive activity of Asp104Ala and Asp104Lys mutant b 1 -ARs by measuring its amount of accumulation and compared with that of WT receptor. The pEC 50 values measured for isoproterenol in wild type and Asp104Ala mutant b 1 -ARs were 7.40Ϯ0.02 and 7.5Ϯ0.01, respectively ( Fig. 2A) . On the other hand, we could not determine the EC 50 value of isoproterenol in Asp104Lys mutant of b 1 -AR (Fig. 2B) .
Constitutive Activation As we previously observed that the Asp104Ala mutant showed the constitutive activity by in- creasing the basal cAMP level with stimulation of 10 mM isoproterenol, we have also examined the constitutive activity of Asp104Lys mutant. The present result showed that the basal level of cAMP in the Asp104Lys mutant was lower compared to wild type b 1 -AR shown in Fig. 3 . On the other hand, isoproterenol induced 2 fold (pϽ0.05) and 4 fold (pϽ0.005) the cAMP production respectively compared to wild type and Asp104Ala mutant of b 1 -AR. As the mutant of Asp104Lys did not show constitutive activity, we could not be able to examine inverse agonist activity of b-blockers. However, (Ϫ)-propranolol, carvedilol and atenolol showed significant inverse agonism by inhibiting the basal level of Asp104Ala mutant receptors.
34)
Western Blot Analysis As the Asp104Lys mutant did not exhibit constitutive activity and eliminated detectable isoproterenol-stimulated cAMP accumulation, Western blotting was performed for examining the expression both b 1 -AR wild-type and mutant receptors. Western blot probed with the anti-b 1 -AR antibody detected and immunoreactive band of about 60 kDa in wild type and both mutants receptor expressing cells (Fig. 4) , as reported earlier for this antibody in HEK293 cells, 42) suggesting that the mutations in TMH II did not cause any abnormality in the receptor proteins. It is also suggested that the mutant proteins are functionally inactive but are still expressed and detectable by antibody.
DISCUSSION
We have previously reported that Asp104 in the b 1 -AR contributes to agonist and antagonist binding through electrostatic interactions between the acidic function oxygen of Asp104 and the hydrogen atom of the trimethyl ammonium of the ligand. 39) Both mutant receptors were expressed in HEK293 cells and assessed for ligand binding affinity and agonist induced cAMP production.
In saturation binding experiment, binding affinity of [
3 H]CGP-12177 was 2 fold decreased for Asp104Lys mutant compared to wild type b 1 -AR (pϽ0.05), whereas number of binding sites (B max ) was also decreased significantly (pϽ0.001). The Western blot experiment demonstrated that receptor expression level was also decreased for Asp104Lys mutant; however, mutant receptor did not interfere with binding experiment of [ 3 H]CGP-12177 radio ligand. Similarly, mutation of highly conserved aspartic acid at position 130 to alanine and asparagine showed low expression in comparison with wild type b 2 -AR. 43) In competition binding, it is evident that the substitution of Asp at position 104 by Lys decreased significantly (pϽ0.05) the binding affinity to isoproterenol and (Ϫ)-epinephrine in comparison with wild type b 1 -AR. On the other hand, binding affinity of several antagonists were unchanged compared to wild type receptor and resulted in monophasic binding curves with Hill slopes close to Unity, which resembles the previous Asp104Ala mutant data, 39) shown in Table 1 and Fig. 2 . Moreover, Asp104Lys mutant might affect the ligandreceptor interaction by distortion of the neighboring amino acid residues due to mutation of negatively charged Asp to positively charged Lys of b 1 -AR, which might cause the repulsion of positively charged trymethyl ammonium of ligand. Similarly, mutant (Asp104Ala) b 1 -AR showed lower binding affinity to several agonists. It had been reported that mutation of Asp79 with alanine in TMH II of b 2 -AR reduced the mostly agonist binding, but not antagonist binding. 44) In the present study, although aspartic acid residue at 104 position of TMH II of b 1 -AR is located in the same homologous position as aspartic acid of 79 residue of b 2 -AR, the mutants Asp104Ala, Asp104Lys and Asp79Ala showed almost similar results.
The aspartic acid residue at position 79 in putative TMH II of b 2 -AR involved in agonist binding and receptor activation. Substitution of aspartic acid to alanine and asparagine at position 79 did not affect the antagonist binding but significantly decreased the binding affinity of agonists. 36, 37) Similarly, our findings suggest that the aspartic acid at position 104 in TMH II of the human b 1 -AR that is conserved in receptor may take part in an ionic interaction with amino group containing catecholamines and whose disruption of interaction make the receptor active conformation state. Moreover, this mutant receptor also affected the functional activity in comparison with wild type receptor by uncoupling with GPCRs. Another recent report also suggested that angiotensin II Type 1 recetpors (AT 1 ) involved in receptor activation by movement of TMH II and TMH VII .
16) The present findings that the Asp104Lys mutant receptor, exhibited no guanine nucleotide-sensitive agonist binding and affected minimal stimulation on adenylate cyclase, imply that the role of this residue in receptor function may not be limited to catecholamine binding. In addition, our results suggest that this locus in TMH II may also be involved in an agonist-induced conformational change, which may facilitate its interaction with GPCRs. Asp104Lys mutant appears to limit the range of possible receptor conformations and thereby prevents the effective transfer of the energy of ligand binding to other effectors. On the other hand, the Asp104Lys mutant of b 1 -AR did not show any constitutive activity with its lowered basal cAMP accumulation in comparison with 100% basal wild type receptor. It had been reported that Cys258Thr mutant of b 2 -AR showed constitutive activity, where other mutant in the same amino acid site Cys285Ser did not show any constitutive activity, similar to wild type characteristics. 45) It was hypothesized that Cys285 acted as rotomar toggle switch which was different from DRY motif responsible for receptor activation. Similarly at our present study, Asp104Lys mutant exhibited the receptor's constitutive inactivation compared to both wild type as well as constitutively active Asp104Ala mutant of b 1 -AR, although the mechanism of these different characteristics is remained to be further examined.
The complete understanding of the structural basis of GPCR activation will require a high-resolution crystal, nuclear magnetic resonance (NMR), and other dynamics experiment that will lead to a better understanding of GPCR signaling and how such signaling can be manipulated with small molecules to therapeutic effect. After getting the crystal structure of rhodopsin, which is also large subfamily of GPCRs, it was possible to describe the agonist and antagonist binding characterization elaborately. 25) Recently, another interesting approach leads to understand the structural basis of GPCRs function, when incorporation of a small T4 lysozyme fusion protein (b 2 -AR-T4L) in third intracellular loop of b 2 -ARs, facilitates the crystallization of hydrophilic region of b 2 -AR. This provides a clue as to how agonist binding is translated into structural changes in the cytoplasmic domains of receptor. 46) It has been proposed that hydrophilic residues may play a role in the structure changes involved in GPCRs activation. 47) Based on simulations in the a 1B adrenergic receptor, Scheer et al. 48) suggested that the Arg131 in the inactive state is constrained in a "polar pocket" formed by residues in TMH I, II, and VII. Upon mutation of the adjacent Asp130 the arginine shifts out of the polar pocket leading to long range conformational changes. The ionic counterpart of the arginine in the inactive state was predicted to be the conserved aspartic acid (79) in TMH II of b 2 -AR. 48) Another report suggested that four amino acids Asp97, Asn318, Asn322 and Y326 of b 2 -AR made a network in b 2 -AR and mutation of these four amino acids showed the uncoupling of GPCRs. 49) The differential effects of this mutant (Asp104Lys) in human b 1 -AR at our present study needs to be further studied to explore the actual facts and the potential therapeutic importance in the cardiovascular diseases.
In conclusion, our results indicate that Asp104 in TMH II of b 1 -AR is an important site for agonists binding for their biological responses. Therefore, the present study with mutation of negatively charged aspartic acid to positively charged lysine as well as neutral charged alanine may help to understand the mechanism of functional characteristics of b 1 -AR and these results may provide the functional responses in relation to b 1 -ARs in several pathophysiology of cardiovascular diseases.
